{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:30Z","timestamp":1747181190436,"version":"3.40.5"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"abstract":"<jats:p>This pilot study aimed to explore the preliminary effects and safety of stereotactic body radiotherapy (SBRT) combined with preventive pelvic radiotherapy and primary gross tumor volumes (GTVp) boost in patients with high-risk prostate cancer based on multiparameter magnetic resonance image (mpMRI). Tumors were contoured as GTVp based on mpMRI. The prostate and proximal seminal vesicles were considered as the clinical target volume1. The pelvic lymphatic drainage area constituted clinical target volume 2. Radiation doses were 40Gy or 45Gy\/5fractions to planning target volume of primary tumor, 37.5Gy\/5f to prostate, seminal vesicle, and positive pelvic lymph nodes, and 25Gy\/5f to pelvic synchronously. The treatment was delivered 3 times per week. Volumetric modulated arc radiotherapy and intensity-modulated radiotherapy were used to complete SBRT. The genitourinary (GU) and gastrointestinal (GI) toxicities were evaluated. Quality of life data was also captured. A total of 15 patients were enrolled in this study with a median age of 78 (56\u201387) from 2017 to 2020. All patients received SBRT. At 3 months after radiotherapy, the proportion of PSA\u2005&lt;\u20050.006\u2009ng\/mL was 66.7% (10\/15). The 2-year biochemical relapse-free survival was 93.3%. The incidence of grade 1 acute GU side effects was 80% (12\/15); the incidence of acute grade 1 GI toxicity was 66.7% (10\/15); and no grade 2 or higher acute GU and GI side effects was observed. Two patients presented with temporary late grade 2 GI toxicity. International Prostatic System Score increased rapidly after a transient increase at 1 week (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001). There were no significant differences in EORTC quality of life scores in all domains except global health status. In this pilot study, it was revealed that SBRT combined with preventive pelvic radiotherapy and GTVp boost based on mpMRI image was effective and well tolerated for patients with high-risk prostate cancer.<\/jats:p>","DOI":"10.1097\/md.0000000000035260","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T17:08:19Z","timestamp":1696007299000},"page":"e35260","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5443","authenticated-orcid":false,"given":"Fang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Abdominal Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Radiology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-6904","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China"},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1177\/1557988318798279","article-title":"Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location.","volume":"12","author":"Taitt","year":"2018","journal-title":"Am J Mens Health"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/COC.0b013e3181cae8c6","article-title":"Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer.","volume":"34","author":"Xu","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/02841860410002824","article-title":"The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.","volume":"44","author":"Fowler","year":"2005","journal-title":"Acta Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","article-title":"What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation.","volume":"115","author":"Zaorsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.","volume":"81","author":"Yeoh","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial.","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer.","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","article-title":"Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.","volume":"23","author":"Lukka","year":"2005","journal-title":"J Clin Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer.","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints.","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13014-016-0758-8","article-title":"Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.","volume":"12","author":"Boyer","year":"2017","journal-title":"Radiat Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2013.05.029","article-title":"Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection.","volume":"109","author":"Abdollah","year":"2013","journal-title":"Radiother Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.","volume":"111","author":"Eifler","year":"2013","journal-title":"BJU Int"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clon.2018.03.004","article-title":"Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high-risk and node-positive prostate cancer.","volume":"30","author":"Murthy","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): early toxicity and quality of life.","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","article-title":"A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer.","volume":"92","author":"Bauman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00066-002-0907-x","article-title":"Interobserver comparison of CT and MRI-based prostate apex definition. Clinical relevance for conformal radiotherapy treatment planning.","volume":"178","author":"Wachter","year":"2002","journal-title":"Strahlenther Onkol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high-risk prostate cancer.","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10585-020-10052-0","article-title":"Adrenal SBRT: a multi-institutional review of treatment outcomes and toxicity.","volume":"37","author":"Helis","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer.","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.mcna.2010.08.013","article-title":"Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).","volume":"95","author":"Roehrborn","year":"2011","journal-title":"Med Clin N Am"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer-results from a multi-institutional clinical trial.","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijrobp.2020.08.014","article-title":"Tumor control probability modeling and systematic review of the literature of stereotactic body radiation therapy for prostate cancer.","volume":"110","author":"Royce","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-9-1","article-title":"Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.","volume":"9","author":"Katz","year":"2014","journal-title":"Radiat Oncol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","article-title":"Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning.","volume":"53","author":"Cellini","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1748-717X-8-84","article-title":"Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.","volume":"8","author":"Aluwini","year":"2013","journal-title":"Radiat Oncol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ijrobp.2016.02.009","article-title":"Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: initial dosimetry analysis and patient outcomes.","volume":"95","author":"Kotecha","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.adro.2018.09.007","article-title":"Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial.","volume":"4","author":"Mcdonald","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.vhri.2016.08.001","article-title":"Conventionally fractionationed volumetric arc therapy versus hypofractionated stereotactic body radiotherapy: quality of life, side effects, and prostate-specific antigen kinetics in localized prostate cancer.","volume":"10","author":"Tambas","year":"2016","journal-title":"Value Health Reg Issues"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jmrs.205","article-title":"First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.","volume":"64","author":"Dixit","year":"2017","journal-title":"J Med Radiat Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:41:25Z","timestamp":1746326485000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":40,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035260","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}